JGC
NKTR icon

J. Goldman & Co’s Nektar Therapeutics NKTR Stock Holding History

J. Goldman & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,352
Closed -$776K – 814
2025
Q4 		$776K Buy
+18,352
New +$1.03M 0.02% 417
2018
Q2 		– Sell
-5,363
Closed -$8.55M – 420
2018
Q1 		$8.55M Buy
5,363
+692
+15% +$892K 0.36% 68
2017
Q4 		$4.18M Sell
4,671
-11,536
-71% -$6.82M 0.22% 122
2017
Q3 		$5.83M Sell
16,207
-11,446
-41% -$3.58M 0.29% 95
2017
Q2 		$8.11M Buy
27,653
+19,976
+260% +$5.77M 0.44% 72
2017
Q1 		$2.7M Sell
7,677
-6,096
-44% -$1.37M 0.13% 186
2016
Q4 		$2.54M Buy
+13,773
New +$2.8M 0.17% 161
2015
Q4 		– Sell
-12,048
Closed -$1.98M – 280
2015
Q3 		$1.98M Buy
+12,048
New +$2.13M 0.17% 144
2013
Q3 		– Sell
-9,667
Closed -$1.68M – 300
2013
Q2 		$1.68M Buy
+9,667
New +$1.48M 0.17% 151

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

J. Goldman & Co's NKTR Position: Q1 2026 in Review

J. Goldman & Co sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 18,352 shares — an estimated $776K sold.

J. Goldman & Co first reported a position in NKTR in Q2 2013 and held it in 9 quarters. The position peaked at $8.55M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • J. Goldman & Co reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 18,352 Nektar Therapeutics shares in Q1 2026, an estimated $776K.
  • J. Goldman & Co first reported a position in Nektar Therapeutics in Q2 2013 and held it in 9 quarters.
  • J. Goldman & Co's Nektar Therapeutics position peaked at $8.55M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.